The proteasomeinhibitor bortezomib is an efficacious apoptotic agent in many tumor cells.
2
Bortezomib is the first proteasomeinhibitor drug tested in human patients.
3
However, a significant proportion of patients who receive a proteasomeinhibitor-containing regime show cardiotoxicity.
4
Therefore, the proteasomeinhibitor MG132 should be further evaluated for combination therapy with TRAIL.
5
The introduction of proteasomeinhibitor and immunomodulatory drugs has considerably changed the treatment paradigm of multiple myeloma.
Ús de proteasome inhibitors en anglès
1
That system is a target for anticancer strategies by using proteasomeinhibitors.
2
Nevertheless, the mechanisms of apoptosis induced by proteasomeinhibitors remain unclear.
3
Both Kyprolis and Velcade are members of a class known as proteasomeinhibitors.
4
Overall, these findings suggest proteasomeinhibitors as potential latency reversing agents.
5
Overall, we determined the unique and novel mechanism of FOXM1 suppression by proteasomeinhibitors.
6
Identification of capzimin offers an alternative path to develop proteasomeinhibitors for cancer therapy.
7
We identified proteasomeinhibitors as the first type of drugs that target FOXM1 in cancer cells.
8
This suggests that proteasomeinhibitors could also be used for rapidly reducing autoantibody production in autoimmune diseases.
9
Overcoming resistance of tumor cells to anticancer agents, such as proteasomeinhibitors, could improve their clinical efficacy.
10
These results indicate that p53 downstream targets can collectively modulate apoptotic response to bortezomib and other proteasomeinhibitors.
11
The introduction of newer proteasomeinhibitors with activity in bortezomib-resistant disease and reduced toxicity profiles may yield further benefits.
12
This was confirmed by the lack of inhibition of IAV entry by proteasomeinhibitors in a virus-like particle fusion assay.
13
Pretreatment of DC with proteasomeinhibitors strongly enhanced the immunogenicity of single viral synthetic as well as bulk LCL peptides.
14
This screen identified 100 genes whose knockdown affected lethality to bortezomib and to a structurally diverse set of other proteasomeinhibitors.
15
The use of proteasomeinhibitors to target cancer's dependence on altered protein homeostasis has been greatly limited by intrinsic a …
16
Moreover, proteasomeinhibitors reduced receptor internalization and degradation, thus implicating a role for the ubiquitination machinery in the trafficking of the beta2AR.